Fifty1 AI Labs LLC identifies new uses for proven medicines using multimodal data-driven research and artificial intelligence. We focus on safe, well-characterized, off-patent compounds to shorten the path to treatment and reduce development costs.
Fifty1 Labs is building a modern platform to support drug repurposing through integrated biomedical data and applied machine learning. Our approach improves the speed and efficiency of drug discovery by focusing on compounds with established safety profiles.
We target wellness-related and broader therapeutic conditions where off-patent drugs may offer new value. As chronic disease and multimorbidity disorders increase globally, there is a pressing need to find holistic solutions to common conditions. Our platform integrates clinical data, chemical models, and regulatory insights to propose candidates for expedited development.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 1505 West 2nd Avenue,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://fifty1ailabs.com/
- Keywords
- Toronto.
- HQ
- Vancouver, BC
Fifty1 Ai Labs Questions
Fifty1 Ai Labs's website is https://fifty1ailabs.com/
Fifty1 Ai Labs's LinkedIn profile is https://www.linkedin.com/company/fifty1-ai-labs
Fifty1 Ai Labs has
7 employees.
View email and phone details for 7
employees at Fifty1 Ai Labs.
Fifty1 Ai Labs's industry is
Biotechnology Research
Fifty1 Ai Labs's top competitors are
Modulink Corporation,
Right Season Investments Corp.,
Lunr,
Base44,
Inka Health (An Onco-Innovations Ltd. Company),
Winchester Securities Corporation,
Xcenda,
Marvik,
Redwood Ai,
Onco-Innovations Ltd. (Cboe: Onco).
Fifty1 Ai Labs's categories are Biotechnology Research
Fifty1 Ai Labs's founding year is 2025
